Skip to content

Biohaven BHVN Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ADMA Biologics logo
ADMA BiologicsADMA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's preferred stock, shares authorized?
Biohaven (BHVN) reported preferred stock, shares authorized of $10M in Q1 2026.
How has Biohaven's preferred stock, shares authorized changed year-over-year?
Biohaven's preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Biohaven's preferred stock, shares authorized?
Over 3 years (2022 to 2025), Biohaven's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.